Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study
Authors' conclusion
Among adults with obesity but without diabetes, GLP-1RA use was associated with reduced cardiovascular, kidney, mortality, and mental health risks compared to other AOMs.
Study context
- Population
- Adults with obesity and no diabetes history, TriNetX electronic health records (July 2021-May 2025)140,169 matched pairs
- Comparison
- GLP-1 RA vs other anti-obesity medications
- Outcome
- Major adverse cardiovascular events (MACE), major adverse kidney events (MAKE) and all-cause mortality
- Follow-up
- Mean 392 days (GLP-1RA) and 564 days (AOM)
Methodological detailspropensity-score matched (1:1), electronic health records (TriNetX)
- Propensity-score matched (1:1)
- Electronic health records (TriNetX)
Main finding
As reported in the abstract
GLP-1RA vs AOMHazard ratio (95% CI)
MACE
0.76(0.72–0.81)
MAKE
0.64(0.55–0.74)
All-cause mortality
0.49(0.42–0.57)
Further findings
| Outcome | HR |
|---|---|
| Mental health outcomesBetween GLP-1RA and AOM · depression | 0.63 |
| Mental health outcomesGLP-1RA vs AOM · suicidal ideation/attempt | 0.42 |
| Mental health outcomesBetween GLP-1RA and AOM · substance use disorder | 0.58 |
Safety
| Outcome | HR |
|---|---|
| Safety outcomesGLP-1RA vs AOM · acute pancreatitis | 1.17 |
| Safety outcomesGLP-1RA vs AOM · hypoglycemia | 1.08 |
| Safety outcomesGLP-1RA vs AOM · gastrointestinal symptoms | 0.99 |
Safety outcomes
- GLP-1RAs not associated with increased risks of acute pancreatitis, hypoglycemia or GI symptoms
Original publication
Cardiovascular and kidney outcomes of GLP ‐1 receptor agonists in adults with obesity: A target trial emulation study. Diabetes Obes Metab. Published 28 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →